ZBIO

ANALYST NOTE: ZBIO (Zenas BioPharma, Inc.) Date: 2026-06-20 Analyst: StoryStocks-Native Equity Research

1. Structural Readiness

Current State: INVALIDATED

• Conservative Entry: None (Setup is invalidated).
• Aggressive Entry: $24.80 (This level is no longer actionable as a forming entry; the structure has broken).
• Breakout Level: $44.60 (The resistance level that would need to be cleared for a new bullish structure to form).
• Extension: Not applicable (Price is below the base structure).

2. The Thesis Layer

Primary Secular Theme: Biotech & GLP-1 → Immunology & Inflammation (Tier Direct, High Confidence).

ZBIO is a direct beneficiary of the secular shift toward targeted immunology therapies. The company's core asset, obexelimab, targets B-cell mediated autoimmune diseases, positioning it squarely within the high-conviction Immunology & Inflammation sub-theme.

• Thesis Strength: The thesis is supported by a clear "direct" exposure. The company is not a diversified conglomerate but a focused clinical-stage biopharmaceutical entity building an I&I (Immunology & Inflammation) focused portfolio.
• Contextual Weight: While the setup is structurally broken, the underlying secular thesis remains intact. The market's reaction (the invalidation) suggests a disconnect between the fundamental progress (positive Phase 3 data) and the capital markets' pricing of that progress, or potentially a liquidity/financing concern not fully captured in the setup metrics. However, the structural breakdown overrides the thematic tailwind for immediate trading purposes.

3. The Business

Company Overview: Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company developing transformative immunology-based therapies.

Business Model & Industry: The company operates in the Healthcare sector, specifically the Biotechnology industry. Its model relies on the development and commercialization of proprietary small molecule and antibody therapies, currently funded by a mix of milestone payments, royalty agreements, and debt financing.

Supporting Evidence (As of 2026-06-20):

• Capital Structure & Liquidity: As of May 13, 2026, the company executed a Loan Agreement securing a $75.0 million tranche (E1). Additionally, pursuant to a Royalty Purchase Agreement, the company received a $75.0 million upfront payment from Royalty Pharma in exchange for a 5.5% royalty on net sales of obexelimab products (E4).
• Commercial Obligations: The company has committed to regulatory milestone payments of up to $75.0 million to BMS, including $10.0 million for FDA marketing authorization submission and $20.0 million for marketing approval (E3).
• Clinical Progress (Obexelimab): In January 2026, the Phase 3 INDIGO trial for IgG4-RD reported positive results, showing a 56% reduction in the risk of flare compared to placebo (Hazard Ratio 0.44, p=0.0005) (E6). Management stated an intent to submit a BLA to the FDA in Q2 2026 (E7) and an MAA to the EMA in the second half of 2026 (E8).
• Pipeline Progress (Orelabrutinib): The Phase 2 MoonStone trial for RMS met its primary endpoint with a 95% relative reduction in new GdE T1 hyperintense lesions (E9). Management expects topline results for this trial in Q4 2026 (E10) and plans to initiate a Phase 3 Monarch trial for non-active SPMS in Q1 2026 (E11).
• Market Opportunity: Management estimates the potential indications represent a multi-billion-dollar commercial opportunity in the U.S. alone (E12).

4. Archetype and Conviction

Archetype: Growth Leader / Clinical Catalyst The company fits the archetype of a clinical-stage growth leader where value is derived from the successful execution of a binary clinical and regulatory roadmap. The "deep value" or "recovery" archetypes do not apply here, as the company is in a high-growth, high-risk development phase, not a distressed turnaround.

Conviction Stack Analysis:

• Thesis Strength: High. The focus on I&I is a dominant secular theme, and the company has a clear, differentiated pipeline (obexelimab and orelabrutinib).
• Evidence Quality: Strong. The evidence base (E1–E13) is robust, citing specific Phase 3 data, regulatory milestones, and significant capital raises ($150M+ in recent liquidity events).
• Rerating Potential: High (Fundamental) / Low (Technical). Fundamentally, the BLA submission (expected Q2 2026) and positive Phase 3 data suggest significant rerating potential. Technically, the structure is broken, requiring a reformation of the base before a new bullish thesis can be acted upon.

Valuation Context: While specific valuation multiples are not provided in the evidence, the receipt of $150M in liquidity (loan + royalty) suggests the company has extended its runway. However, the stock price decline below the breakout structure implies the market is currently discounting the near-term execution risk or the dilutive nature of the capital structure.

5. Invalidating/Strengthening Factors & Gaps

What Would Invalidate the Case Further:

• Regulatory Delay: If the FDA does not accept the BLA submission in Q2 2026 as planned, or if the agency requests additional data, the thesis would be severely damaged.
• Liquidity Crunch: If the $150M raised in 2026 is insufficient to reach the next commercial milestone, forcing a dilutive equity raise at depressed prices.

What Would Strengthen the Case:

• FDA Acceptance: Confirmation of BLA filing acceptance in Q2 2026.
• Positive Phase 3 Monarch Data: Successful initiation and positive early readouts for the SPMS trial.

Gaps in Evidence:

• Cash Burn Rate: The evidence confirms capital raised ($150M) but does not explicitly state the quarterly burn rate or the exact runway remaining as of June 2026.
• Competitive Landscape: No specific evidence regarding competitive pressures from other GLP-1 or immunology therapies in the IgG4-RD or RMS markets.
• Management Guidance on Dilution: No explicit statement on whether the company plans further equity raises or if the current capital structure is sufficient for the full commercialization timeline.

PRIVATE ANALYST CALL

Judgment: Sell Confidence: high Key risks: Potential regulatory delays for BLA submission; Liquidity concerns if burn rate exceeds current runway; Market discounting of binary clinical catalysts. Sizing hint: Position size should be zero; capital preservation is the priority until structure is reformed. Expected path: Management expects BLA submission in Q2 2026 and Phase 3 initiation in Q1 2026; however, the market has priced in a negative reaction to the current price level, requiring a structural reformation before any bullish thesis can be re-engaged. Expected horizon: Indefinite until price reclaims $24.18; likely 3-6 months for a new base to form if fundamentals hold. Failure mode to watch: A sustained close below $19.00, which would indicate a deeper breakdown and potential liquidity distress.